Abstract: A compound comprising a peptide moiety comprising, consisting essentially of, or consisting of, the peptide sequence of a tyrosine cluster YC of the BY-kinase of a Gram positive or Gram negative bacteria, or a fragment or an analogue thereof, and an adenine peptide analogue PNA(A), whereas the peptide moiety and the PNA are linked together. The compound is useful as an inhibitor of bacterial tyrosine kinase.

Abstract: The invention concerns the use of at least a protein of the CRMP family, a polypeptide fragment or an active biological derivative thereof, a nucleotide sequence or sequence fragment coding for said protein, an antisense sequence capable of being specifically hybridized with a sequence with nucleotide-type encoding of said protein or an antibody directed against said protein for producing a medicine for treating diseases related to a dysfunction of the immune system. The invention also concerns a method for diagnosing an autoimmune pathology which consists in measuring the expression of a CRMP protein in the lymphocytes.

Abstract: The invention relates to a method for obtaining a composite ferro-electric material, consisting of the following stages: particles of a ferro-electric compound are covered with a dielectric layer; a dense composite material is formed by sintering the covered particles. The invention is characterized in that in the covering stage the particles of the ferro-electric compound are brought into contact with a fluid containing at least one solvent and a precursor of the dielectric compound, said fluid being pressurized.

Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.

Abstract: The invention concerns a purified polypeptide, called ULIP6, comprising an amino acid sequence SEQ ID NO 2, the nucleic acid coding for said polypeptide, a non-coding sequence in 3? of said encoding sequence and their use in diagnosis and treatment of cancers and paraneoplastic neurological syndromes.

Abstract: The invention relates to the use of proteins designated ULIP/POP in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes.

Abstract: The invention concerns a purified polypeptide, biologically active polypeptide derivative or fragment of said purified polypeptide, comprising an amino acid sequence selected among SEQ.ID. No. 2, No. 4, No. 6 and No. 8.

Abstract: The invention concerns the use of at least a protein of the CRMP family, a polypeptide fragment or an active biological derivative thereof, a nucleotide sequence or sequence fragment coding for said protein, an antisense sequence capable of being specifically hybridized with a sequence with nucleotide-type encoding of said protein or an antibody directed against said protein for producing a medicine for treating diseases related to a dysfunction of the immune system. The invention also concerns a method for diagnosing an autoimmune pathology which consists in measuring the expression of a CRMP protein in the lymphocytes.

Abstract: The invention concerns a purified polypeptide, called ULIP6, comprising an amino acid sequence SEQ ID NO 2, the nucleic acid coding for said polypeptide, a non-coding sequence in 3′ of said encoding sequence and their use in diagnosis and treatment of cancers and paraneoplastic neurological syndromes.